Dr. Devinsky’s research, which was recently published in The New England Journal of Medicine, is beginning to provide that much-needed data in the field of epilepsy research. In a landmark multinational randomized double-blind study for a treatment-resistant form of the condition, subjects taking an oral solution of 20 mg CBD per kilogram of body weight for 14 weeks, along with standard treatment, experienced a 42 percent reduction in drop seizures (the muscles go limp). Those taking a 10 mg CBD per kilogram of body weight saw a 37 percent decrease; patients who got a placebo saw a 17.2 percent decrease. The mechanism hasn’t quite been worked out yet, Dr. Devinsky says, though there’s some evidence that a receptor known as GPR55 may be critical for the anti-seizure effect.
With the rapid rise in the popularity of CBD in everything from vape juice to lattes, many people are asking- “what is CBD oil?”. To answer that question, let’s first answer the question- what is CBD? CBD, short for cannabidiol, is a compound found in hemp plants. CBD’s benefits are numerous, making it a popular supplement. We’ll explore the effects of CBD oil in more depth below, but in short, it interacts with receptors that keep the body balanced and running normally.
That being said, though, CBD isolate still has a very relevant place in the cannabis market. A lot of people, for instance, use it to concoct their own personal daily CBD remedies – they mix the pure powder with oil, or they add it into their coffee, or they make edibles out of it. Since it comes in an easily-measurable powder, it’s a great option for those individuals who are trying to calculate exact personal dosages of CBD medication by the milligram.
A study published by David Cheng, Postdoctoral Scientist, Neuroscience Research, University of New South Wales, NSW, Australia, says that CBD has a potential as a preventive measure against symptoms of Alzheimer’s. This presents yet another exciting development for medical researchers, given the persistent challenges to finding effective solutions for this condition.
Because the FDA considers CO2 extraction to be GRAS or “generally regarded as safe” for commercial extraction, this method is popular in the food industry. The stability of supercritical CO2 also allows most compounds to be extracted with little damage. In the coffee industry, supercritical CO2 is already widely accepted as safer than traditional solvents to extract the caffeine from decaffeinated coffee beans.
Unfortunately, you don’t. Even though more than half of all U.S. states now allow marijuana for medicinal purposes—and nine of those, plus Washington DC, allow it for recreational use—the Drug Enforcement Agency still views CBD as a banned substance and therefore doesn’t regulate it (since, in the eyes of the law, CBD shouldn’t be on the market). “I can start a company, put oil in a jar and sell it as CBD oil,” says McLaughlin—and no one has to vouch that what’s in there is for real. You have only the manufacturers word for it.
Instead, the human body manages cannabinoids through its endocannabinoid system, also known as ECS, which can process CBD and hemp oil through the body and is managed by the human brain, which uses cannabinoids to regulate the body's physiological reactions to the herb, and help better manage key human elements like eating, sleeping, dealing with pains and illnesses, and improving mood.
CBD isolate is pure CBD, extracted and purified until none of the plant’s other constituent compounds remain. It has been isolated down to just the CBD molecule. This purity and potency is why it’s the preferred treatment for patients needing unadulterated doses of CBD and nothing else. It has no other active ingredients and its purpose is simply to deliver therapeutic doses of CBD. CBD isolate products often come as a white powder or a mix with a oil.
Zuardi, A. W., Crippa, J. A., Hallak, J. E., Bhattacharyya, S., Atakan, Z., Martin-Santos, R., … & Guimarães, F. S. (2012). A critical review of the antipsychotic effects of cannabidiol: 30 years of a translational investigation [Abstract]. Current Pharmaceutical Design, 18(32), 5,131–5,140. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/22716160